title: Oxymorphone: a review.
abstract: Oxymorphone (oxymorphone hydrochloride) (14-hydroxy-dihydromorphinone), a semisynthetic mu-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.
authors.affiliation: VIP Palliative Care Program Greater Los Angeles Healthcare, Division of Hematology/Oncology, UCLA School of Medicine, 11301 Wilshire 111-H, Los Angeles, CA, USA. eric.prommer@med.va.gov
authors.forename: Eric
authors.initials: E
authors.lastname: Prommer
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D006801:Humans; D009369:Neoplasms / Q000150:complications; D010111:Oxymorphone / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy*
chemical_list: D000701:Analgesics, Opioid; D010111:Oxymorphone